Receive our newsletter – data, insights and analysis delivered to you
January 21, 2016

Pharma companies urge governments to take collective action on drug-resistant infections

Around 85 international pharmaceutical, generics, diagnostics and biotechnology firms have urged governments and industry to take comprehensive action on drug-resistant infections called superbugs.

By Ranjith Dharma

Around 85 international pharmaceutical, generics, diagnostics and biotechnology firms have urged governments and industry to take comprehensive action on drug-resistant infections called superbugs.

The firms have launched a joint declaration at the World Economic Forum in Davos, Switzerland, calling for collective action on antimicrobial resistance.

The Declaration on Combating Antimicrobial Resistance has been signed by 85 companies and nine industry associations from 18 countries.

Some of the commercial drug and diagnostic developers have also agreed on a common set of principles for global action to support antibiotic conservation and the development of new drugs, diagnostics, and vaccines.

"This declaration will greatly help the growing movement to tackle resistance to antibiotics, and boost the many firms and people working to win the Longitude Prize."

The industry has urged governments across the globe to support companies to invest in the development of antibiotics, diagnostics, vaccines and other products to be used for the prevention and treatment of drug-resistant infections.

The signatory companies have urged the governments to collaborate with them to develop new and alternative market structures, which provide more dependable and sustainable market models for antibiotics.

Content from our partners
How Hengst helped to keep Germany’s charity “star singers” shining
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Patient-centric pharma logistics: How CRYOPDP delivers hope worldwide

The declaration has recommended certain measures for its signatories to take action on drug resistance, including reducing the development of drug resistance, increasing investment in R&D and improving access to high-quality antibiotics.

Nesta CEO and Longitude Committee member Geoff Mulgan said: "This declaration will greatly help the growing movement to tackle resistance to antibiotics, and boost the many firms and people working to win the Longitude Prize for a novel and rapid point of care diagnostic test, one of the crucial building blocks for an effective global strategy on AMR."

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU